Acadia Pharmaceuticals (ACAD) Net Cash Flow (2010 - 2026)

Acadia Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $104.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 202.56% year-over-year to $104.5 million; the TTM figure through Mar 2026 stood at $63.5 million (up 295.74% YoY), while the FY2025 annual figure was -$142.8 million, down 206.58% from the prior year.
• Net Cash Flow for Q1 2026 stood at $104.5 million, up from -$81.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $176.1 million in Q1 2023, with the low at -$180.6 million in Q2 2023.
• The 5-year median for Net Cash Flow is $4.4 million (2025), against an average of $8.1 million.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow soared 366.79% in 2022, then slumped 733.51% in 2025.
• Acadia Pharmaceuticals' Net Cash Flow stood at -$40.0 million in 2022, then jumped by 326.26% to $90.5 million in 2023, then surged by 81.82% to $164.5 million in 2024, then sank by 149.81% to -$81.9 million in 2025, then soared by 227.53% to $104.5 million in 2026.
• Business Quant data shows ACAD's Net Cash Flow at $104.5 million in Q1 2026, -$81.9 million in Q4 2025, and $4.4 million in Q3 2025.